Genmab A/S ADS (GMAB) Earnings

Genmab A/S ADS

GMAB · Nasdaq

Symbol: GMAB
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: Europe
Exchange: Nasdaq

Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody drug conjugate (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab's science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific.

Key Issues

Bullish view

Genmab reported three positive Phase III readouts across lymphoma, ovarian cancer and head-and-neck cancer, which MarketBeat says could support potential product launches beginning in 2027.

Bearish view

Positive trial readouts do not establish regulatory approval or commercial launches, and the supplied evidence does not give launch-specific revenue estimates.

Analyst Consensus

See all

Buy

18 analysts

$56

Current

—

Low

$44

Average

—

High

Average target implies -21.93% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Biogen Inc.BIIB · Nasdaq

Genmab A/S ADS

Next quarter

GMAB Jun 2026